8-K: Genprex's Reqorsa Shows Strong Preclinical Lung Cancer Data

Genprex announced positive preclinical data for its lead drug candidate, Reqorsa Gene Therapy, in ALK-EML4 positive non-small cell lung cancer, demonstrating superior tumor shrinkage in combination therapy.

Summary

• Genprex's research collaborators will present positive preclinical data for Reqorsa Gene Therapy (quaratusugene ozeplasmid, QO) at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics.
• The data focuses on QO for the treatment of ALK-EML4 positive non-small cell lung cancer (NSCLC).
• In vitro studies showed QO-mediated overexpression of tumor suppressor candidate 2 (TUSC2) significantly induced apoptosis in ALK+ cell lines and patient-derived organoids.
• QO demonstrated a robust pro-apoptotic response in ALK+ NSCLC cell lines with acquired resistance to the ALK inhibitor, alectinib, reducing cell viability when treated in combination with alectinib.
• In an in vivo mouse study, alectinib alone shrunk tumors by 60%, while QO alone and in combination with alectinib shrunk tumors by 79%.
• This finding indicates that QO has a 23% improved outcome in tumor shrinkage compared to alectinib alone.
• Researchers hypothesize that QO may be an ideal companion drug for patients with advanced disease or a treatment for patients who cannot tolerate alectinib.
• Tumors in mice that received single-drug treatment are regrowing faster than tumors in mice that received combined treatment of QO and alectinib, two weeks after the end of treatment.

Sentiment

Score: 8

Explanation: The preclinical data is very positive, showing superior efficacy and potential to address drug resistance in a significant cancer indication. This is a strong step forward for the company's lead candidate. However, it is still preclinical, and significant risks remain in clinical development and commercialization.

Positives

• Reqorsa Gene Therapy (QO) significantly induced apoptosis in ALK+ NSCLC cell lines and patient-derived organoids through TUSC2 overexpression.
• QO demonstrated effectiveness in ALK+ NSCLC cell lines that had acquired resistance to alectinib, a common ALK inhibitor.
• In an in vivo mouse model, QO alone and in combination with alectinib achieved 79% tumor shrinkage, outperforming alectinib alone which resulted in 60% shrinkage.
• The combination therapy of QO and alectinib showed a 23% improved outcome in tumor shrinkage compared to alectinib monotherapy.
• Combined treatment led to slower tumor regrowth compared to single-drug treatments in mice, suggesting sustained efficacy.
• The preclinical data supports the potential for a clinical trial for REQORSA as a treatment for ALK-EML4 positive translocated NSCLC.

Risks

• Ability to advance the clinical development, manufacturing, and commercialization of product candidates in accordance with projected timelines.
• Timing and success of clinical trials and regulatory approvals, including beliefs about REQORSA's potential as a therapeutic treatment.
• Uncertainty regarding the effects of product candidates, alone and in combination with other therapies, on cancer and diabetes.
• Effects of any strategic research and development prioritization initiatives and the ability to implement such efforts successfully.
• Ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern.
• Ability to obtain capital to meet long-term liquidity needs on acceptable terms, or at all.
• Risks associated with commercial and strategic partnerships, including those with third-party vendors, suppliers, and manufacturers.
• Risks related to intellectual property and licenses.
• Actual results may differ materially from forward-looking statements due to various important factors.

Future Outlook

The in vitro and in vivo data suggest that QO mediated overexpression of TUSC2 in ALK+ NSCLC is effective in decreasing growth and proliferation through the activation of apoptotic pathways, thereby paving the way for a potential clinical trial for REQORSA as a potential treatment for ALK-EML4 positive translocated NSCLC. Researchers are also currently monitoring mice for survival, with initial observations indicating slower tumor regrowth in combined treatment groups.

Management Comments

• The company's research suggests that QO may be an ideal companion drug for patients with advanced disease or a treatment for patients who cannot tolerate alectinib.
• In vitro and in vivo data indicate that QO mediated overexpression of TUSC2 in ALK+ NSCLC is effective in decreasing growth and proliferation through the activation of apoptotic pathways, potentially paving the way for a clinical trial for REQORSA.

Industry Context

This announcement highlights Genprex's progress in the highly competitive oncology space, specifically targeting ALK-EML4 positive NSCLC, a subset of lung cancer often associated with resistance to existing ALK inhibitors like alectinib. The positive preclinical data, particularly the improved efficacy and potential to overcome resistance, positions Reqorsa as a promising candidate in a market seeking more effective and combination therapies for advanced and resistant cancers. The focus on gene therapy also aligns with broader industry trends towards novel therapeutic modalities.

Comparison to Industry Standards

• Reqorsa (QO) demonstrated a 23% improved outcome in tumor shrinkage compared to alectinib alone in an in vivo mouse model. Alectinib (Alecensa) is a second-generation ALK inhibitor developed by Roche, widely used for ALK-positive NSCLC.
• The ability of QO to induce apoptosis and reduce cell viability in ALK+ NSCLC cell lines with acquired resistance to alectinib addresses a significant unmet medical need in the industry, as resistance to targeted therapies is a common challenge.
• The preclinical results suggest Reqorsa could potentially enhance the efficacy of existing ALK inhibitors, similar to how other combination therapies are being explored in oncology to improve patient outcomes and overcome resistance mechanisms.

Stakeholder Impact

• Shareholders: Positive preclinical data could increase investor confidence and potentially lead to share price appreciation, but significant risks remain regarding future clinical trials and capital needs.
• Patients: The data offers hope for a new, potentially more effective treatment option for ALK-EML4 positive NSCLC, especially for those with advanced disease or resistance to current therapies.
• Medical Community: The findings contribute to the understanding of ALK+ NSCLC treatment and the potential role of gene therapy and combination approaches.
• Employees: Positive research outcomes can boost morale and validate ongoing R&D efforts.

Next Steps

• Presentation of preclinical data at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26, 2025).
• Potential clinical trial for REQORSA as a treatment for ALK-EML4 positive translocated NSCLC.
• Continued monitoring of mice for survival and tumor measurements.

Key Dates

Recommendation

While the preclinical data for Reqorsa is highly promising, demonstrating superior efficacy and potential to overcome resistance in ALK+ NSCLC, it remains early-stage. The transition from preclinical to successful clinical trials is fraught with significant risks, and the company explicitly highlights ongoing concerns about capital needs and maintaining Nasdaq listing. A 'hold' recommendation acknowledges the strong scientific progress and potential upside but also factors in the substantial execution risks and future financing requirements inherent in biotechnology development.

Keywords

Genprex, Reqorsa, quaratusugene ozeplasmid, QO, ALK-EML4 positive NSCLC, Non-Small Cell Lung Cancer, Gene Therapy, Preclinical Data, Apoptosis, TUSC2, Alectinib, Oncology, Cancer Therapeutics, Biotechnology, Clinical Trials